M42, a first-of-its-kind health powerhouse in UAE, and Broad Institute of MIT and Harvard will work with Microsoft and the International Center for Genetic Disease (ICGD).
The group will leverage the Terra platform to explore scenarios for precision health discovery and delivery, collaborating with healthcare organizations across the global ecosystem.
Terra, a secure, scalable, open-source platform for biomedical researchers to access data, run analysis tools, and collaborate, will provide the foundational technology to enable data science, life science, and precision medicine growth in the UAE while contributing to the availability of more diverse genomic datasets for human health research globally. Terra was co-developed by Broad Institute, Microsoft, and Verily.
Ashish Koshy Group COO – M42
“At M42’s core is the development of impactful technologies and solutions that will, and are already, significantly benefiting our understanding of disease and population health. The agreement between M42 and Broad Institute working together with Microsoft is a milestone in our efforts to advance clinico-genomic infrastructure and further develop our world-class data science capabilities. Our use of Terra on Azure as the foundation for M42’s Global Life Sciences Platform will vastly accelerate our efforts to transform global research collaborations as well as unlock new drug discoveries and a new generation of omics-powered clinical trials.”
Terra, which will be deployed on the UAE cloud with sovereign capabilities powered by Microsoft Azure, will be used not only as a Trusted Research Environment but also as the foundation for M42’s Global Life Sciences Platform.
This supports the intent to advance M42’s data science capabilities for clinical and genomic data integration, access, and research, and to improve patient lives and inform scientific research across the world.
M42’s Global Life Sciences Platform will leverage existing Microsoft Azure Health Data Services, generative AI-based data models, host advanced tools including M42’s generative AI model, Med42, and drive interoperability and advanced analytics for both research and clinical care. It will allow multi-party users to access data, deploy analytical tools, and derive insights in a safe and secure environment for clinical research and drug discovery.
Thank you very much for choosing GCC Business News to be an important part of your professional life. You will receive a confirmation e-mail. Please check SPAM or UPDATES folder
